US equities
|
MU
$888.33
▼-2.82%
NVDA
$216.13
▼-2.34%
SNDK
$1,316.92
▼-6.16%
SPCX
$145.82
▼-4.16%
AMD
$537.67
▼-5.81%
INTC
$92.45
▼-5.77%
TSM
$413.50
▼-3.84%
AAPL
$344.76
▲+0.52%
MU
$888.33
▼-2.82%
NVDA
$216.13
▼-2.34%
SNDK
$1,316.92
▼-6.16%
SPCX
$145.82
▼-4.16%
AMD
$537.67
▼-5.81%
INTC
$92.45
▼-5.77%
TSM
$413.50
▼-3.84%
AAPL
$344.76
▲+0.52%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
bluebird bio, Inc. - Common Stock
(NQ:
BLUE
)
4.970
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about bluebird bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm
April 02, 2024
From
Schall Law
Via
GlobeNewswire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)
April 02, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors
April 01, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
↗
March 27, 2024
Via
Benzinga
Peering Into bluebird bio's Recent Short Interest
↗
March 22, 2024
Via
Benzinga
BLUE LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE
March 31, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. (BLUE)
March 30, 2024
From
Robbins LLP
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors
March 29, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
March 29, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm
March 29, 2024
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors
March 29, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
BLUE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
March 29, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
↗
March 29, 2024
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.
Via
The Motley Fool
BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm
March 28, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
↗
March 28, 2024
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia.
Via
Investor's Business Daily
bluebird bio, Inc. (NASDAQ: BLUE) Financial Restatement: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc.
March 28, 2024
NEW YORK, NY - (NewMediaWire) - March 28, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click...
Via
NewMediaWire
bluebird bio, Inc. (NASDAQ: BLUE) Financial Restatement: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc.
March 28, 2024
NEW YORK, NY - (NewMediaWire) - March 28, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click...
Via
TheNewswire.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
March 28, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
BLUEBIRD ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Bluebird Stockholders and Encourages Investors to Contact the Firm
March 27, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
March 27, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Bluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities Violations
March 27, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Bluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities Violations
March 27, 2024
NEW YORK, NY - (NewMediaWire) - March 27, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click...
Via
TheNewswire.com
The Law Offices of Frank R. Cruz Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
March 27, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
BLUE LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
March 27, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
March 26, 2024
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click...
Via
NewMediaWire
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
March 26, 2024
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click...
Via
TheNewswire.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 26, 2024
Via
Benzinga
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
March 26, 2024
From
bluebird bio, Inc.
Via
Business Wire
Earnings Scheduled For March 26, 2024
↗
March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
Via
Benzinga
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
March 25, 2024
From
bluebird bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
